Biomedical papers, 2016 (vol. 160), issue 2

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016, 160(2):183-194 | 10.5507/bp.2015.050

Renal cell carcinoma: Review of etiology, pathophysiology and risk factors

Nadezda Petejovaa,b, Arnost Martineka,b
a Department of Internal Medicine, University Hospital Ostrava, Czech Republic
b Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Czech Republic

Background and Aims: The global incidence of renal cell cancer is increasing annually and the causes are multifactorial. Early diagnosis and successful urological procedures with partial or total nephrectomy can be life-saving. However, only up to 10% of RCC patients present with characteristic clinical symptoms. Over 60% are detected incidentally in routine ultrasound examination. The question of screening and preventive measures greatly depends on the cause of the tumor development. For the latter reason, this review focuses on etiology, pathophysiology and risk factors for renal neoplasm.

Methods: A literature search using the databases Medscape, Pubmed, UpToDate and EBSCO from 1945 to 2015.

Results and Conclusions: Genetic predisposition/hereditary disorders, obesity, smoking, various nephrotoxic industrial chemicals, drugs and natural/manmade radioactivity all contribute and enviromental risks are a serious concern in terms of prevention and the need to screen populations at risk. Apropos treatment, current oncological research is directed to blocking cancer cell division and inhibiting angiogenesis based on a knowledge of molecular pathways.

Keywords: hereditary syndromes, nephrectomy, radioactivity, renal cell carcinoma, renal carcinogenesis, uranium toxicity

Received: May 4, 2015; Accepted: September 18, 2015; Prepublished online: November 3, 2015; Published: June 24, 2016


References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11Lyon, France: International Agency for Research on Cancer [Internet]. 2013 [cited 2015 March 3]; Available from: http://globocan.iarc.fr and www.wcrf.org
  2. Remon J, Lianes P, Martínez S. Brain metastases from renal cell carcinoma. Should we change the current standard? Cancer Treat Rev 2012;38(4):249-57. Go to original source... Go to PubMed...
  3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49(1):8-31. Go to original source... Go to PubMed...
  4. Aydin H, Chen L, Cheng L, Vaziri S, He H, Ganapathi R, Delahunt B, Magi-Galluzzi C, Zhou M. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol 2010;34(11):1608-21. Go to original source... Go to PubMed...
  5. Gobbo S, Eble JN, Maclennan GT, Grignon DJ, Shah RB, Zhang S, Martignoni G, Brunelli M, Cheng L. Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am J Surg Pathol 2008;32(12):1780-6. Go to original source... Go to PubMed...
  6. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010;7(5):245-57. Go to original source... Go to PubMed...
  7. Dmitriev AA, Rudenko EE, Kudryavtseva AV, Krasnov GS, Gordiyuk VV, Melnikova NV,Stakhovsky EO, Kononenko OA, Pavlova LS, Kondratieva TT, Alekseev BY, Braga EA, Senchenko VN, Kashuba VI. Epigenetic alterations of chromosome 3 revealed by NotI-microarrays in clear cell renal cell carcinoma. Biomed Res Int 2014;2014:735292. Go to original source... Go to PubMed...
  8. Cairns P. Renal cell carcinoma. Cancer Biomark 2010;9(1-6):461-73. Go to original source... Go to PubMed...
  9. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005;353(23):2477-90. Go to original source... Go to PubMed...
  10. Belldegrun AS, Klatte T, Shuch B, LaRochelle JC, Miller DC, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Dekernion JB, Pantuck AJ. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008;113(9):2457-63. Go to original source... Go to PubMed...
  11. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF,Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23(1):133-41. Erratum in: J Clin Oncol 2005; 23(12):2877. Go to original source... Go to PubMed...
  12. Brauch H, Weirich G, Brieger J, Glavac D, Rödl H, Eichinger M, Feurer M, Weidt E, Puranakanitstha C, Neuhaus C, Pomer S, Brenner W, Schirmacher P, Störkel S, Rotter M, Masera A, Gugeler N, Decker HJ.VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000;60(7):1942-8. Go to PubMed...
  13. Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ 2014;349:g4797. Go to original source... Go to PubMed...
  14. Vortmeyer AO, Lubensky IA, Fogt F, Linehan WM, Khettry U, Zhuang Z.Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol 1997;151(4):951-6. Go to PubMed...
  15. Tse JY, Wong JH, Lo KW, Poon WS, Huang DP, Ng HK. Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol 1997;107(4):459-66. Go to original source... Go to PubMed...
  16. Haas NB, Nathanson KL. Hereditary kidney cancer syndromes. Adv Chronic Kidney Dis 2014;21(1):81-90. Go to original source... Go to PubMed...
  17. Gossage L, Murtaza M, Slatter AF, Lichtenstein CP, Warren A, Haynes B,Marass F, Roberts I, Shanahan SJ, Claas A, Dunham A, May AP, Rosenfeld N, Forshew T, Eisen T. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma. Genes Chromosomes Cancer 2014;53(1):38-51. Go to original source... Go to PubMed...
  18. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin ML, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LF, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469(7331):539-42. Erratum in: Nature 2012;484(7392):130. Go to original source... Go to PubMed...
  19. Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, Leng N, Pavía-Jiménez A, Wang S, Yamasaki T, Zhrebker L, Sivanand S, Spence P, Kinch L, Hambuch T, Jain S, Lotan Y, Margulis V, Sagalowsky AI, Summerour PB, Kabbani W, Wong SW, Grishin N, Laurent M, Xie XJ, Haudenschild CD, Ross MT, Bentley DR, Kapur P, Brugarolas J. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44(7):751-9. Erratum in: Nat Genet 2012; 44(9):1072. Go to original source... Go to PubMed...
  20. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA.Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463(7279):360-3. Go to original source... Go to PubMed...
  21. George CM, Stadler WM, Vogelzang NJ. Primary neoplasms of the kidney and renal pelvis. In: Schrier RW, editor. Diseases of the kidney and urinary tract, Philadelphia: Lippincott Williams &Wilkins; 2001. p. 831-49.
  22. Breen EC. VEGF in biological control. J Cell Biochem 2007;102(6):1358-67. Go to original source... Go to PubMed...
  23. Rydzanicz M, Wrzesiński T, Bluyssen HA, Wesoły J. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett 2013;341(2):111-26. Go to original source... Go to PubMed...
  24. Teloken PE, Houston Thompson R, Tickoo SK, Cronin A, Savage C, Reuter VE. Russo P. Prognostic impact of histological subtype in patients with surgically treated localized renal cell carcinoma. J Urol 2009;182(5): 2132-6. Go to original source... Go to PubMed...
  25. Fernandes DS, Lopes JM. Pathology, therapy and prognosis of papillary renal carcinoma. Future Oncol 2015;11(1):121-32. Go to original source... Go to PubMed...
  26. Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C,Choyke P, Grubb R, Middelton L, Turner ML, Walther MM, Merino MJ, Zbar B, Linehan WM, Toro JR. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006; 43(1):18-27. Go to PubMed...
  27. Gellera C, Uziel G, Rimoldi M, Zeviani M, Laverda A, Carrara F, DiDonato S. Fumarase deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes. Neurology 1990;40:495-9. Go to original source... Go to PubMed...
  28. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007;31(10):1578-85. Go to original source... Go to PubMed...
  29. Schmidt LS, Warren MB, Nickerson ML, Weirich G, Matrosova V, Toro JR,Turner ML, Duray P, Merino M, Hewitt S, Pavlovich CP, Glenn G, Greenberg CR, Linehan WM, Zbar B.Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001;69(4):876-82. Go to original source... Go to PubMed...
  30. Johannesma PC, van Moorselaar RJ, Horenblas S, van der Kolk LE, Thunnissen E, van Waesberghe JH,Menko FH, Postmus PE. Bilateral renal tumour as indicator for birt-hogg-dubé syndrome. Case Rep Med 2014;2014:618675. Go to original source... Go to PubMed...
  31. Morrison PJ, Donnelly DE, Atkinson AB, Maxwell AP. Advances in the genetics of familial renal cancer.Oncologist 2010;15(6):532-8. Go to original source... Go to PubMed...
  32. Gupta R, Billis A, Shah RB, Moch H, Osunkoya AO, Jochum W, Hes O, Bacchi CE, de Castro MG, Hansel DE, Zhou M, Vankalakunti M, Salles PG, Cabrera RA, Gown AM, Amin MB. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol 2012;36(9):1265-78. Go to original source... Go to PubMed...
  33. Davis CJ Jr, Mostofi FK, Sesterhenn IA. Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 1995;19(1):1-11. Go to original source... Go to PubMed...
  34. Becker F, Junker K, Parr M, Hartmann A, Füssel S, Toma M,Grobholz R, Pflugmann T, Wullich B, Strauss A, Behnes CL, Otto W, Stöckle M, Jung V. Collecting duct carcinomas represent a unique tumor entity based on genetic alterations. PLoS One 2013;8(10):e78137. Go to original source... Go to PubMed...
  35. Reuter VE, Gaudin PB. Adult renal tumors. In: Sternberg SS, editor. Diagnostic surgical pathology. Philadelphia: JB Lippincott; 1999. p. 1785-818.
  36. Biswas B, Wahal SP, Gulati A. Renal oncocytoma: A diagnostic dilemma on cytology. J Cytol 2014;31(1):59-60. Go to original source... Go to PubMed...
  37. Trpkov K, Yilmaz A, Uzer D, Dishongh KM, Quick CM, Bismar TA, Gokden N. Renal oncocytoma revisited: a clinicopathological study of 109 cases with emphasis on problematic diagnostic features. Histopathology 2010;57:893-906. Go to original source... Go to PubMed...
  38. Perez-Ordonez B, Hamed G, Campbell S, Erlandson RA, Russo P, Gaudin PB, Reuter VE. Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol 1997;21:871-83. Go to original source... Go to PubMed...
  39. Zhao W, Tian B, Wu C, Peng Y, Wang H, Gu WL, Gao FH. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma. Pathol Res Pract 2015;211(4):303-7. Go to original source... Go to PubMed...
  40. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371(9612):569-78. Go to original source... Go to PubMed...
  41. Li L, Kalantar-Zadeh K. Obesity that makes kidney cancer more likely but helps fight it more strongly. J Natl Cancer Inst 2013;105(24):1848-9. Go to original source... Go to PubMed...
  42. Zhang GM, Zhu Y, Ye DW. Metabolic syndrome and renal cell carcinoma. World J Surg Oncol 2014;12:236. Go to original source... Go to PubMed...
  43. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004;56(4):549-80. Go to original source... Go to PubMed...
  44. Ying HQ, Sun HL, He BS, Pan YQ, Wang F, Deng QW, Chen J, Liu X, Wang SK. Circulating vitamin D binding protein, total, free and bioavailable 25-hydroxyvitamin D and risk of colorectal cancer. Sci Rep 2015;5:7956. Go to original source... Go to PubMed...
  45. Anic GM, Weinstein SJ, Mondul AM, Männistö S, Albanes D. Serum vitamin D, vitamin D binding protein, and lung cancer survival. Lung Cancer 2014;86(3):297-303. Go to original source... Go to PubMed...
  46. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006;372(1-2):33-42. Go to original source... Go to PubMed...
  47. Mondul AM, Weinstein SJ, Moy KA, Männistö S, Albanes D. Vitamin D-binding protein, circulating vitamin D and risk of renal cell carcinoma. Int J Cancer 2014; 134(11):2699-706. Go to original source... Go to PubMed...
  48. Khan MI, Bielecka ZF, Najm MZ, Bartnik E, Czarnecki JS, Czarnecka AM, Szczylik C. Vitamin D receptor gene polymorphisms in breast and renal cancer: current state and future approaches (review). Int J Oncol 2014;44(2):349-63. Go to PubMed...
  49. Karami S, Brennan P, Hung RJ, Boffetta P, Toro J, Wilson RT, Zaridze D, Navratilova M, Chatterjee N, Mates D, Janout V, Kollarova H, Bencko V, Szeszenia-Dabrowska N, Holcatova I, Moukeria A, Welch R, Chanock S, Rothman N, Chow WH, Moore LE.Vitamin D receptor polymorphisms and renal cancer risk in Central and Eastern Europe.J Toxicol Environ Health A 2008;71(6):367-72. Go to original source... Go to PubMed...
  50. Arjumand W, Ahmad ST, Seth A, Saini AK, Sultana S. Vitamin D receptor FokI and BsmI gene polymorphism and its association with grade and stage of renal cell carcinoma in North Indian population. Tumour Biol 2012;33(1):23-31. Go to original source... Go to PubMed...
  51. Agundez JA. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004;5(3):211-24. Go to original source... Go to PubMed...
  52. Khlifi R, Messaoud O, Rebai A, Hamza-Chaffai A. Polymorphisms in the human cytochrome P450 and arylamine N-acetyltransferase: susceptibility to head and neck cancers. Biomed Res Int 2013;2013:582768. Go to original source... Go to PubMed...
  53. Meng FD, Ma P, Sui CG, Tian X, Jiang YH. Association between cytochrome P450 1A1 (CYP1A1) gene polymorphisms and the risk of renal cell carcinoma: a meta-analysis. Sci Rep 2015;5:8108. Go to original source... Go to PubMed...
  54. Ostry V, Malir F, Ruprich J. Producers and important dietary sources of ochratoxin A and citrinin.Toxins (Basel) 2013;5(9):1574-86. Go to original source... Go to PubMed...
  55. Malir F, Ostry V, Pfohl-Leszkowicz A, Novotna E. Ochratoxin A: developmental and reproductive toxicity-an overview. Birth Defects Res B Dev Reprod Toxicol 2013;98(6):493-502. Go to original source... Go to PubMed...
  56. International Agency for research on cancer[Internet]. 1993 [cited 2015 June 22]; Available from: http://monographs.iarc.fr/.
  57. Malir F, Ostry V, Pfohl-Leszkowicz A, Roubal T. Ochratoxin A exposure biomarkers in the Czech Republic and comparison with foreign countries. Biomarkers 2012;17(7):577-89. Go to original source... Go to PubMed...
  58. Pfohl-Leszkowicz A, Manderville RA. An update on direct genotoxicity as a molecular mechanism of ochratoxin a carcinogenicity. Chem Res Toxicol 2012;25(2):252-62. Go to original source... Go to PubMed...
  59. Hibi D, Suzuki Y, Ishii Y, Jin M, Watanabe M, Sugita-Konishi Y, Yanai T, Nohmi T, Nishikawa A, Umemura T. Site-specific in vivo mutagenicity in the kidney of gpt delta rats given a carcinogenic dose of ochratoxin A.Toxicol Sci 2011;122(2):406-14. Go to original source... Go to PubMed...
  60. Akman SA, Adams M, Case D, Park G, Manderville RA. Mutagenicity of ochratoxin A and its hydroquinone metabolite in the SupF gene of the mutation reporter plasmid Ps189. Toxins (Basel) 2012;4(4):267-80. Go to original source... Go to PubMed...
  61. Pfohl-Leszkowicz A, Molinié A, Tozlovanu M, Manderville RA. Combined Toxic Effects of Ochratoxin A and Citrinin in Vitro and in Vivo, In: Food Contaminats: Mycotoxins & Food Allergens; Siantar DP, Trucksess MW, Scott PM, Herman EM Eds; American Chemical Society Symposium Series, 1001, American Society of Microbiology: Washington D.C., USA, 2008; pp.56-80.
  62. Boesch-Saadatmandi C, Loboda A, Jozkowicz A, Huebbe P, Blank R, Wolffram S, Dulak J, Rimbach G. Effect of ochratoxin A on redox-regulated transcription factors, antioxidant enzymes and glutathione-S-transferase in cultured kidney tubulus cells. Food Chem Toxicol 2008;46(8):2665-71. Go to original source... Go to PubMed...
  63. Heussner AH, Dietrich DR, O'Brien E. In vitro investigation of individual and combined cytotoxic effects of ochratoxin A and other selected mycotoxins on renal cells. Toxicol In Vitro 2006;20(3):332-41. Go to original source... Go to PubMed...
  64. Grenier, B; Oswald, IP. Mycotoxin co-contamination of food and feed: meta-analysis of publications describing toxicological interactions. World Mycotoxin J 2011;4(3):285-313. Go to original source...
  65. Manderville, R.; Pfohl-Leszkowicz, A. Bioactivation and DNA Adduction as a Rationale for Ochratoxin A Carcinogenesis. World Mycotoxin J 2008;1:357-67. Go to original source...
  66. Barrisford GW, Singer EA, Rosner IL, Linehan WM, Bratslavsky G. Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol 2011; 2011: 658767. Go to original source... Go to PubMed...
  67. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004;4(5):381-93. Go to original source... Go to PubMed...
  68. Genetics of kidney cancer (Renal Cell Cancer): National Cancer Institute. [Internet]. [cited 2015 March 22]; Available from: http:// www. cancer.gov/.
  69. FaCD online, Familial Cancer Database.[Internet]. [cited 2015 March 25]; Available from: http://www.familialcancerdatabase.nl/
  70. Malchoff CD, Sarfarazi M, Tendler B, Forouhar F, Whalen G, Joshi V, Arnold A, Malchoff DM. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J Clin Endocrinol Metab 2000;85(5):1758-64. Go to PubMed...
  71. De la Rosette JMCH, Sternberg CN, Van Poppel HPA. Renal Cell Cancer Diagnosis and therapy. London: Springer Verlag; 2008: p. 166.
  72. De Waele L, Lagae L, Mekahli D. Tuberous sclerosis complex: the past and the future. Pediatr Nephrol 2014; DOI 10.1007_s00467-014-3027-9.
  73. Ferrer Márquez M, Moreno Serrano A, Maturana Ibáñez V, Reina Duarte A. Lynch syndrome-associated kidney cancer. Rev Esp Enferm Dig 2011;103(6):339-40. Go to PubMed...
  74. Alvaro E, Alegre C, Perea J. Association between Lynch syndrome and renal carcinoma. Rev Esp Enferm Dig 2011;103(9):500-1. Go to original source... Go to PubMed...
  75. Zhang T, Boswell EL, McCall SJ, Hsu DS. Mismatch repair gone awry: Management of Lynch syndrome. Crit Rev Oncol Hematol 2015;93(3):170-9. Go to original source... Go to PubMed...
  76. Hemminki K, Li X. Familial renal cell cancer appears to have a recessive component. J Med Genet 2004;41(5):e58. Go to original source... Go to PubMed...
  77. Moch H, Montironi R, Lopez-Beltran A, Cheng L, Mischo A. Oncotargets in different renal cancer subtypes. Curr Drug Targets 2015;16(2):125-35. Go to original source... Go to PubMed...
  78. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009;11(10):687-94. Go to original source... Go to PubMed...
  79. Farley MN, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PL, Eng C, Linehan WM, Brugarolas J. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 2013;11(9):1061-71. Go to original source... Go to PubMed...
  80. Tollefson MK, Boorjian SA, Lohse CM, Blute ML, Leibovich BC. The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma. BJU Int 2010;106(11):1638-42. Go to original source... Go to PubMed...
  81. Woodward ER. Familial non-syndromic clear cell renal cell carcinoma. Curr Mol Med 2004;4(8):843-8. Go to original source... Go to PubMed...
  82. Hamilton JM. Renal carcinogenesis. Adv Cancer Res 1975;22:1-56. Go to original source... Go to PubMed...
  83. Kirkman H, Bacon RL. Estrogen-induced tumors of the kidney. II. Effect of dose, administration, type of estrogen, and age on the induction of renal tumors in intact male golden hamsters. J Natl Cancer Inst 1952;13(3):757-71. Go to PubMed...
  84. Algard FT. Action of sex hormones on dependent tumors in cell and organ-culture systems. Natl Cancer Inst Monogr 1963;11:215-26. Go to PubMed...
  85. Ward DN, Putch JD, Adams-Mayne M. Estrogen-induced kidney tumors in the golden hamster. 3. Luteinizing hormone levels in the pituitary gland during tumorigenesis. Cancer Res 1965;25(10):1781-3. Go to PubMed...
  86. Mabuchi K, Soda M, Ron E, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasaki M, Preston DL, Thompson DE. Cancer incidence in atomic bomb survivors. Part I: Use of the tumor registries in Hiroshima and Nagasaki for incidence studies. Radiat Res 1994;137(2 Suppl):S1-16. Go to original source... Go to PubMed...
  87. Thompson DE, Mabuchi K, Ron E, Soda M, Tokunaga M, Ochikubo S, Sugimoto S, Ikeda T, Terasaki M, Izumi S, Preston DL. Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987.Radiat Res 1994;137(2 Suppl):S17-67. Erratum in: Radiat Res 1994;139(1):129. Go to PubMed...
  88. Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K. Solid cancer incidence in atomic bomb survivors: 1958-1998.Radiat Res 2007;168(1):1-64. Go to original source... Go to PubMed...
  89. Romanenko A, Morell-Quadreny L, Nepomnyaschy V, Vozianov A, Llombart-Bosch A. Pathology and proliferative activity of renal-cell carcinomas (RCCS) and renal oncocytomas in patients with different radiation exposure after the Chernobyl accident in Ukraine. Int J Cancer2000;87(6):880-3. Go to original source... Go to PubMed...
  90. Suzuki K, Yamashita S. Low-dose radiation exposure and carcinogenesis. Jpn J Clin Oncol 2012;42(7):563-8. Go to original source... Go to PubMed...
  91. Yao Y, Dai W. Genomic Instability and Cancer. J Carcinog Mutagen. 2014;5. pii: 1000165.
  92. Kern SE. Progressive Genetic Abnormalities in Human Neoplasia. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The Molecular Basis of Cancer, Philadelphia: W.B. Saunders Company; 2001. p.41-63.
  93. Ye S, Yuan D, Xie Y, Pan Y, Shao C. Role of DNA methylation in the adaptive responses induced in a human B lymphoblast cell line by long-term low-dose exposures to γ-rays and cadmium. Mutat Res Genet Toxicol Environ Mutagen 2014;773:34-8. Go to original source... Go to PubMed...
  94. Lasseigne BN, Burwell TC, Patil MA, Absher DM, Brooks JD, Myers RM. DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Med 2014;12(1):235. Go to original source... Go to PubMed...
  95. Anderson JL, Daniels RD, Fleming DA, Tseng CY. Exposure assessment for a cohort of workers at a former uranium processing facility. J Expo Sci Environ Epidemiol 2012;22(4):324-30. Go to original source... Go to PubMed...
  96. Medley DW, Kathren RL, Miller AG. Diurnal urinary volume and uranium output in uranium workers and unexposed controls. Health Phys 1994;67(2):122-30. Go to original source... Go to PubMed...
  97. Haley DP, Bulger RE, Dobyan DC.The long-term effects of uranyl nitrate on the structure and function of the rat kidney. Virchows Arch B Cell Pathol Incl Mol Pathol 1982;41(1-2):181-92. Go to original source... Go to PubMed...
  98. Committee on the Biological Effects of Ionizing Radiation BEIR IV. Health risk of radon and other internally deposited alpha-emitters. Washington D.C: National Academy Press; 1988. pp.276-303.
  99. Thun MJ, Baker DB, Steenland K, Smith AB, Halperin W, Berl T. Renal toxicity in uranium mill workers. Scand J Work Environ Health 1985;11(2):83-90. Go to original source... Go to PubMed...
  100. Milligan MF. Fluorophotometric determinations of uranium in urine and air. Proceedings of the Bioassay and Analytical Meeting. USAES Report NLCO-595.1955.
  101. Montie JE, Levin SH. Detection and Diagnosis of Renal Cell Carcinoma In: Montie JE, Pontes JE, Bukowski RM, Editors. Clinical Management of Renal Cell Cancer. Chicago, London, Boca Raton, Littleton, Mass: Year Book Medical Publishers INC;1987. pp.6-90.
  102. Fukumoto S, Matsumoto T, Yamoto H, Kawashima H, Ueyama Y, Tamaoki N, Ogata E. Suppression of serum 1,25-dihydroxyvitamin D in humoral hypercalcemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25-dihydroxyvitamin D3 production. Endocrinology1989;124(5):2057-62. Go to original source... Go to PubMed...
  103. Rajpara A, Liolios A, Fraga G, Blackmon J. Recurrent paraneoplastic wells syndrome in a patient with metastatic renal cell cancer. Dermatol Online J 2014;20(6):pii:13030/qt35w8r1g3.
  104. Wells GC. Recurrent granulomatous dermatitis with eosinophilia. Trans St Johns Hosp Dermatol Soc 1971;57(1):46-56. Go to PubMed...
  105. Morla D, Alazemi S, Lichtstein D. Stauffer's Syndrome Variant with Cholestatic Jaundice A Case Report. J Gen Intern Med 2006;21(7):C11-C13. Go to original source... Go to PubMed...
  106. Stauffer MH. Nephrogenic hepatomegaly. Gastroenterology 1961;40:694.
  107. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic Syndromes in Urologic Malignancy: The Many Faces of Renal Cell Carcinoma. Reviews in urology 2002;4:163-70. Go to PubMed...
  108. Ljungberg B, Cowan N, Hanbury D.C, Hora M, Kuczyk M.A, Merseburger A.S, Mulders P.F.A, Patard J-J, Sinescu I.C. Guidelines on Renal Cell Carcinoma. Eur Urol 2007;51(6):1502-10. Go to original source... Go to PubMed...
  109. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7thed. New York, NY: Springer-Verlag; 2010, p.43.
  110. Ljungberg B, Bensalah K, Bex A, Canfield S, Dabestani S, Hofmann F Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders PFA, Powles T, Staehler M, Volpe A. Guidelines on renal cell carcinoma. European Association of Urology [Internet]. 2013 [cited 2015 January 10]; Available from:http://www.uroweb.org/
  111. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A. EAU Guidelines on Renal Cell Carcinoma: 2014 Update. Eur Urol 2015;67(5):913-24. Go to original source... Go to PubMed...
  112. Pantuck AJ, Belldegrun AS, Figlin RA. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy? Clin Cancer Res 2007;13(2 Pt 2):693-6. Go to original source... Go to PubMed...
  113. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345(23):1655-9. Go to original source... Go to PubMed...
  114. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966-70. Go to original source... Go to PubMed...
  115. Stroup SP, Raheem OA, Palazzi KL, Liss MA, Mehrazin R, Kopp RP, Patel N, Cohen SA, Park SK, Patterson AL, Kane CJ, Millard F, Derweesh IH. Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study. Urology 2013;81(4):805-11. Go to original source... Go to PubMed...
  116. Han X, Shang D, Han T, Xu X, Tian Y. Interferon-α enhances the susceptibility of renal cell carcinoma to rapamycin by suppressing mTOR activity. Exp Ther Med 2014;8(1):267-73. Go to original source... Go to PubMed...
  117. Payne R, Glenn L, Hoen H, Richards B, Smith JW 2nd, Lufkin R, Crocenzi TS, Urba WJ, Curti BD. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer 2014;2:13. Go to original source... Go to PubMed...
  118. Fishman M, Seigne J. Immunotherapy of metastatic renal cell cancer. Cancer Control 2002;9(4):293-304. Go to PubMed...
  119. Asmana Ningrum R. Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo) 2014;2014:970315. Go to original source... Go to PubMed...
  120. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315(3):971-9. Go to original source... Go to PubMed...
  121. Czarnecka AM, Szczylik C, Rini B. The use of sunitinib in renal cell carcinoma: where are we now? Expert Rev Anticancer Ther 2014;14(9):983-99. Go to original source... Go to PubMed...
  122. Livne-Segev D, Gottfried M, Maimon N, Peer A, Neumann A, Hayat H, Kovel S, Sella A, Mermershtain W, Rouvinov K, Boursi B, Weitzen R, Berger R, Keizman D. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. Isr Med Assoc J 2014;16(6):347-51. Go to PubMed...